单位：[1]Mil Chinese Peoples Liberat Army, Hosp 307, Beijing, Peoples R China[2]Zhengzhou Univ, Affiliated Canc Hosp, Dept Hematol, Zhengzhou, Henan, Peoples R China河南省肿瘤医院[3]Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China[4]Dalian Med Univ, Hosp 2, Dept Oncol, Dalian, Peoples R China[5]Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Zhejiang, Peoples R China浙江大学医学院附属第一医院[6]Peking Union Med Coll Hosp, Beijing, Peoples R China[7]Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China河北医科大学第四医院[8]Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China[9]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Hubei, Peoples R China华中科技大学同济医学院附属同济医院[10]Guangzhou Med Univ, Canc Hosp, Guangzhou, Guangdong, Peoples R China[11]Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China四川大学华西医院[12]Chinese Acad Med Sci, Blood Inst, Tianjin, Peoples R China[13]Jilin Univ, Hosp 1, Ctr Canc, Jilin, Jilin, Peoples R China[14]ChangHai Hosp, Shanghai, Peoples R China[15]Shandong Univ, Qilu Hosp, Jinan, Shandong, Peoples R China[16]Cent S Univ, Xiangya Hosp, Dept Oncol, Changsha, Hunan, Peoples R China[17]Chinese Acad Med Sci, Beijing Key Lab Clin Study Anticanc Mol Targeted, Dept Med Oncol, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China[18]Peking Union Med Coll, Beijing, Peoples R China[19]Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, Beijing, Peoples R China[20]Peking Union Med Coll, Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China[21]Innovent Biol Suzhou Co Ltd, Suzhou, Peoples R China
Su Hang,Song Yongping,Jiang Wenqi,et al.Sintilimab for relapsed/refractory classical Hodgkin's lymphoma: Extended follow-up on the multicenter, single-arm phase II ORIENT-1 study[J].JOURNAL OF CLINICAL ONCOLOGY.2019,37(15):
APA：
Su, Hang,Song, Yongping,Jiang, Wenqi,Sun, Xiuhua,Qian, Wenbin...&Wang, Shuyan.(2019).Sintilimab for relapsed/refractory classical Hodgkin's lymphoma: Extended follow-up on the multicenter, single-arm phase II ORIENT-1 study.JOURNAL OF CLINICAL ONCOLOGY,37,(15)
MLA：
Su, Hang,et al."Sintilimab for relapsed/refractory classical Hodgkin's lymphoma: Extended follow-up on the multicenter, single-arm phase II ORIENT-1 study".JOURNAL OF CLINICAL ONCOLOGY 37..15(2019)
医学